Mildronat injection and parabulbarly 10% 5ml ampoules 10 pcs


Mildronat injection and parabulbarly 10% 5ml ampoules 10 pcs



Hypersensitivity to Mildronatu®, increased intracranial pressure (in violation of the venous outflow, intracranial tumors).
100 mg / ml
In the treatment of coronary heart disease (angina, myocardial infarction), congestive heart failure and cardiomyopathy dyshormonal, as well as in the treatment of acute and chronic disorders of the brain blood supply (cerebral strokes and cerebrovascular insufficiency).
Hemophthalmus and retinal hemorrhages of varying etiology, central venysetchatki thrombosis and its branches, retinopathy of various etiologies (diabetic, hypertension).
Reduced performance; physical strain, including athletes.
withdrawal syndrome in chronic alcoholism (in combination with specific alcoholism therapy).
Interaction with other drugs
Enhances the action vasodilatig funds, some antihypertensive drugs,
cardiac glycosides. Can be combined with antianginal agents, anticoagulants,
antiplatelet agents, antiarrhythmic agents, diuretics, bronchodilators. Due to the possible development of moderate tachycardia and hypotension, caution should be exercised when combined with nitroglycerin, nifedipine, alpha-blockers,
antihypertensive agents and peripheral vasodilators.
Mildronata cases of overdose are not known. The drug has low toxicity and does not cause side effects that are hazardous to the health of patients.
pharmachologic effect
Pharmacological properties:
Mildronate® – structural analog of gamma-butyrobetaine – a substance that is found in every cell of the human body.
In high load conditions Mildronate® restores the balance between the delivery and demand of cells in oxygen, eliminates the accumulation of toxic products of metabolism in the cells, protecting them from damage;
Also shows a tonic effect. As a result of its use of the body gains the ability to withstand stress and quickly restore energy reserves. Because of these properties Mildronate® used to treat a variety of disorders of the cardiovascular system, the blood supply to the brain, as well as to improve physical and mental performance. By lowering the concentration of carnitine intensively synthesized gamma-butyrobetaine possesses vasodilating properties. In the case of acute myocardial ischemic injury Mildronate® inhibits the formation of necrotic zone shortens the rehabilitation period. In heart failure, myocardial contractility increases, increases exercise tolerance, reduces the frequency of angina attacks. In acute and chronic ischemic disorders of cerebral blood circulation improves blood circulation in the ischemic focus, promotes redistribution of blood to the ischemic area. It is effective in the case of vascular and dystrophic pathology of the fundus. The drug eliminates functional disorders of the nervous system in patients with chronic alcoholism during abstinence syndrome.
After oral administration, the drug is rapidly absorbed, bioavailability – 78%. Maximum plasma concentration is achieved 1-2 hours after administration. It is metabolized in the body into two major metabolites are excreted by the kidneys. The half-life when administered depends on the dose of 3-6 hours.
Pregnancy and breast-feeding
Safety of the drug during pregnancy has not been proved.
To avoid possible adverse effects on the fetus during pregnancy, it is not prescribed.
It is not clear whether the drug is excreted in the mother’s milk. If treatment with Mildronate®
the mother is necessary, breast-feeding is stopped.
Conditions of supply of pharmacies
On prescription.
side effects
Rarely – allergic reactions (redness, rash, itching, swelling) and dyspepsia, tachycardia, changes in blood pressure, arousal.
special instructions
Patients with chronic liver diseases and kidney caution during prolonged application of the drug.
There is insufficient data on the use mildronata children.
Years of experience in the treatment of acute myocardial infarction and unstable angina Cardiac offices shows that trimethylhydrasine propionate dihydrate is not a first-line drug for acute coronary syndrome.
Effects on ability to drive and served by other mechanisms
No evidence of adverse effects of the drug on Mildronate® reaction rate.
Storage conditions
Store at a temperature not higher than 25 ° C. Do not freeze! Keep out of the reach of children.
Dosing and Administration
In view of the possible development of stimulating effect it is recommended to use in the morning.
1. Cardiovascular diseases. In the combined therapy of 0.5-1 g per day orally or intravenously (5-10 ml of solution for injection 0.5 g / 5 ml), applying the entire dose at once or by dividing it into 2
times. The course of treatment – 4-6 weeks. Cardialgia on background dyshormonal myocardial dystrophy –
inside, 0.25 g of 2 times per day. The course of treatment – 12 days.
2. Violation of the cerebral circulation. Acute phase – 0,5 g 1 times a day intravenously for 10 days, passing to intake of 0.5-1 g per day. The total course of treatment – 4-6 weeks.
Chronic disorders – 0.5 g orally per day. The total course of treatment – 4-6 weeks.
Repeated courses (usually 2-3 times a year) are possible after consultation with the doctor.
3. Vascular pathology and dystrophic diseases of the retina. Parabulbarno 0.5 mL solution for injection 0.5 g / 5 ml for 10 days.
4. The mental and physical overload, including athletes. Adults 0.25g inside 4
times a day or intravenously at 0.5 g 1 time per day. The course of treatment – 10-14 days. If necessary, repeat the treatment after 2-3 weeks.
Athletes of 0.5-1 g orally 2 times a day before training. The duration of the course during the preparatory period – 14-21 days, during the period of competition – 10-14 days.
5. Chronic alcoholism. Inside of 0.5 g 4 times a day; IV – 0.5 g 2 times per day.
The course of treatment – 7-10 days.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review